EU MDR Article 117 Implementation Plan for Drug–Device Combinations in 2023: Documentation Checklist

The implementation of Article 117 under the EU Medical Device Regulation (EU MDR) places significant demands on stakeholders involved in drug-device combinations. This comprehensive guide outlines the step-by-step process necessary to ensure compliance with Article 117, providing a detailed checklist for documentation and submissions. By following these structured actions, you can effectively navigate the regulatory landscape for drug-device products.

Step 1: Understand the Regulatory Framework

Article 117 of the EU MDR specifically pertains to the evaluation of the conformity of medicinal products that incorporate a medical device. Understanding this regulation is crucial for regulatory teams, especially for US-based entities looking to market their drug-device combinations in Europe.

Drug-device combinations may include products such as pre-filled syringes, inhalers, and drug-eluting stents. These innovative products require rigorous assessment by a Notified Body that is designated under MDR provisions. Familiarity with definitions, the general safety and performance requirements (GSPR), and the concept of essential requirements in Annex II is critical.

For proper implementation, consider the following key aspects:

• Definition of Drug-Device Combinations: Understand what constitutes a combination product and how it is evaluated under both medicinal and medical device regulations.
• Relevant Guidelines: Familiarize yourself with guidance documents provided by regulatory authorities, including but not limited to the European Commission.
• Role of Notified Bodies: Grasp the importance of collaborating with an appropriate Notified Body for conformity assessment.

By equipping your team with a sound understanding of the regulatory framework, you set a foundation for successful compliance as you move forward in the process.

Step 2: Engage with a Notified Body

Engaging with a Notified Body is the next critical step in the Article 117 implementation plan. Notified Bodies are responsible for the conformity assessment of combination products to ensure adherence to EU regulations.

The selection of a Notified Body should be based on specific criteria including:

• Scope of Designation: Verify that the Notified Body is designated for the classification of the combination product you are developing.
• Experience and Expertise: Consider the Notified Body’s experience with similar products and their understanding of drug-device regulatory intersections.
• Communication and Responsiveness: Establish clear communication channels and responsiveness for effective collaboration throughout the evaluation process.

Upon securing a partnership with a Notified Body, initiate a pre-submission meeting to discuss your product and confirm the requirements for documentation. This collaboration outlines expectations for both parties and identifies areas requiring additional focus in your compliance strategy.

Step 3: Prepare Key Technical Documentation

Article 117 mandates that organizations prepare extensive technical documentation to support their claims and demonstrate compliance with GSPR. This documentation is often encapsulated within the Technical File and Design Dossier.

Your technical documentation must include:

• Product Descriptions: Comprehensive descriptions of the combined product, including intended use, design, principles of operation, and mode of action.
• Risk Management File: A structured file that addresses potential risks associated with the drug-device combination, referencing ISO 14971 standards for risk management.
• Performance and Safety Data: Data from preclinical and clinical studies, which may include results from pivotal trials to substantiate safety and efficacy claims.
• Labeling and Instructions for Use: Complete labeling information in accordance with the EU MDR and any specific requirements regarding drug and device elements.

Compiling this documentation requires meticulous attention to detail. Ensure that your documents are organized and easily navigable. Electronic submission through systems like EUDAMED may require you to format your documents according to specific templates provided by the Notified Body.

Step 4: Develop a Conformity Assessment Strategy

Establishing a conformity assessment strategy is fundamental to fulfilling the mandates of Article 117. This strategy lays out a roadmap indicating how the information compiled in your Technical Documentation will be submitted for review by the Notified Body.

Your strategy should include:

• Type of Conformity Assessment: Identify the appropriate assessment route—whether it falls under Annex VII, VIII, or IX of EU MDR—for your specific combination product.
• Clinical Evaluation Plan: Develop a robust clinical evaluation plan, detailing how clinical data will be generated and assessed in light of the combination product.
• Regulatory Pathway: Articulate the regulatory pathway and requirements that bridge both drug and device regulations, ensuring all necessary evaluations are outlined.

The Notified Body will expect a well-defined strategy that signifies your thorough preparation and understanding of compliance dynamics associated with drug-device combinations. Document any anticipated challenges and strategies to mitigate them as part of your submission preparation.

Step 5: Conduct a Clinical Evaluation

Conducting a clinical evaluation is a pivotal component under Article 117. It involves systematically reviewing available clinical data and literature to support the safety and effectiveness of the product.

The clinical evaluation should encompass:

• Existing Data Review: Systematically gather published literature relevant to your drug and device components, assessing their clinical performance and results.
• Clinical Trial Execution: If existing data is insufficient, consider conducting clinical trials that align with both EU regulatory expectations and Good Clinical Practice (GCP) guidelines.
• Documentation of Results: Document all findings thoroughly in the Clinical Evaluation Report (CER), which serves as a critical part of your submission.

Ensure that the CER addresses all required elements under the EU MDR, including justification for the clinical data obtained and how it supports compliance with safety and performance requirements. Regularly updating the CER is essential as new data becomes available or when significant product changes occur.

Step 6: Submission of Documentation to Notified Body

Once all prerequisites are established, prepare for the formal submission of your Technical Documentation to the Notified Body. Submissions should be comprehensive and align with the specific guidelines provided by the Notified Body.

Consider the following guidelines during submission:

• Compiling Submission Documents: Formulate a checklist encompassing all necessary documents, ensuring that nothing is overlooked.
• Format Compliance: Confirm that all documents adhere to the specified formats for electronic submissions, as required by the Notified Body.
• Communication Protocols: Maintain clear communication with the Notified Body regarding submission timelines, review process expectations, and any precursory assessments required.

The submission itself is a critical milestone. Ensure all documentation is complete and error-free to facilitate a smooth review process. Be prepared to answer queries or provide additional information as requested by the Notified Body during the assessment period.

Step 7: Participation in the Review Process

Following the submission, your team will be engaged in the review process carried out by the Notified Body. This stage is critical to achieving compliance with Article 117.

The review process typically includes several phases:

• Initial Review: An initial assessment where the Notified Body confirms if the submitted documentation is complete and fulfills the relevant regulatory requirements.
• Detailed Evaluation: A more comprehensive evaluation where the efficacy and safety data are rigorously examined.
• Feedback and Queries: Anticipate feedback that may require clarifications or additional information. Responding to queries in a timely manner demonstrates diligence and professionalism.

Engaging proactively with the Notified Body during this phase can facilitate a smoother review process. Regular updates and follow-ups can mitigate potential delays and rework that may arise from compliance issues.

Step 8: Post-Approval Commitments

Upon receiving approval, the essential work continues. Post-market surveillance and vigilance are integral to compliance with Article 117, ensuring continued safety and effectiveness of the drug-device combination once it enters the market.

Key activities include:

• Adverse Event Reporting: Establish robust systems for monitoring adverse events and reporting them as per regulatory guidelines.
• Post-Market Clinical Follow-Up (PMCF): Design a PMCF study if required by the Notified Body or to further substantiate the clinical data used in your initial application.
• Periodic Safety Update Reports (PSUR): Regularly generate PSURs that consolidate information on the safety profile of the product based on real-world data.

These actions reaffirm your commitment to regulatory compliance and product safety, significantly impacting your reputation and market success. Integral to maintaining market authorization, these ongoing activities will also inform iterative improvements to both the drug and device components of your combination product.

Notified Body Opinion (NBOp) for Article 117: How US Sponsors Prepare in 2023

The implementation of Article 117 of the EU Medical Device Regulation (EU MDR) marks a significant transition for US sponsors developing combination products that incorporate medicinal substances. Navigating the requirements for Notified Body Opinion (NBOp) can be daunting, given the stringent expectations set forth by European legislation. This guide aims to provide a step-by-step tutorial on how US sponsors can prepare for the NBOp process effectively, ensuring compliance and optimizing the chances for a successful outcome.

Step 1: Understanding the Requirements of Article 117

Article 117 of the EU MDR pertains to combination products where a medical device incorporates an active substance intended for medicinal purposes. This regulation mandates that a Notified Body provides an opinion confirming that the medical device component complies with the relevant provisions of the EU MDR. Understanding the scope and implications of Article 117 is crucial for US sponsors before initiating the submission process.

The first step is to thoroughly review the specific provisions under Article 117 and how they apply to your product. The key elements to consider include:

• Combination Product Definition: Determine if your product qualifies as a combination product as defined by the EU MDR.
• Notified Body Designation: Ensure that you select a Notified Body that is designated under the EU MDR and has experience with combination products.
• General Safety and Performance Requirements (GSPR): Familiarize yourself with the GSPR outlined in Annex I, which must be fulfilled by your medical device component.
• Documentation File Preparation: Collect and prepare appropriate documentation as outlined in Annex II, as this will be vital for the assessment by the Notified Body.

Equipped with this foundational understanding, sponsors can set the stage for successful compliance with Article 117 requirements.

Step 2: Assembling the Technical Documentation

Success in obtaining a Notified Body Opinion under Article 117 hinges on comprehensive technical documentation. The documentation serves as proof of compliance with all relevant EU regulations and standards. It is essential that the technical file be compiled meticulously to avoid any discrepancies that could hinder the approval process.

The technical documentation should include the following components:

• Device Description: A detailed overview of the device, including its components, principles of operation, and intended purpose.
• Design and Manufacturing Information: Documentation detailing how the device is designed and manufactured, including quality control measures in place.
• Safety and Performance Data: Evidence of safety and performance, including clinical and preclinical study data, if applicable.
• Risk Management Report: A thorough risk management report in compliance with ISO 14971, demonstrating the identification and mitigation of any potential risks associated with the device.
• Labeling and Instructions for Use: Samples of intended labels and user instructions that comply with EU requirements.
• Post-Market Surveillance Plan: A comprehensive plan for monitoring the device post-approval, including methods for gathering data on adverse events.

Each section of the technical documentation must be written clearly and succinctly. Consider involving EU MDR consulting services to ensure all regulatory requirements are explicitly met. Having a solid technical file enhances the prospects of a favorable Notified Body Opinion.

Step 3: Identifying and Engaging a Notified Body

Choosing the right Notified Body is a critical step in the process. As a US sponsor, you need to ensure that the Notified Body selected is appropriate for your specific product type and has the necessary expertise and accreditation. The selection process can be complex, given there are numerous organizations with different specialties.

To select a Notified Body, follow these steps:

• Research Designated Notified Bodies: Use the European Commission’s official list of designated Notified Bodies under the EU MDR.
• Evaluate Capabilities: Assess potential Notified Bodies for their experience with combination products and their track record of successfully providing opinions on similar applications.
• Initiate Engagement: Once you have identified suitable Notified Bodies, initiate engagement discussions. This may include preliminary meetings to discuss your product and assess the body’s willingness to provide the necessary opinion.
• Request a Quotation: Obtain quotes from multiple Notified Bodies to evaluate costs associated with the evaluation process.

It is imperative that you maintain open communication with your chosen Notified Body throughout the process, providing them with all necessary documentation and updates about the project’s status. Establishing a solid working relationship is essential for a smooth review process.

Step 4: Preparing and Submitting the Application for NBOp

With the technical documentation compiled and a Notified Body selected, the next step is to formally prepare the application for the Notified Body Opinion. This application must clearly demonstrate that the medical device meets all applicable safety and performance requirements.

The application should comprise the following elements:

• Cover Letter: A brief introduction that summarizes the purpose of the application and highlights key points regarding the device and its intended use.
• Technical File: Include the comprehensive technical documentation assembled in the previous step as part of the application to the Notified Body.
• Evidence of Notified Body Engagement: Include documentation demonstrating previous communications with the Notified Body, indicating a mutual understanding of the evaluation process.
• Additional Information: Any other relevant information that the Notified Body may require to perform a thorough evaluation, including regulatory history and existing certifications.

Once all components are gathered, review the entire submission package for completeness and accuracy prior to submission. Follow the specific submission process outlined by the Notified Body, as each organization may have unique requirements for how documents should be submitted (electronically, paper copies, etc.).

Step 5: Addressing Queries and Comments from the Notified Body

After the submission, the Notified Body will conduct a thorough review of your application. During this phase, it is common to receive queries or requests for clarification concerning the data provided in your submission. It is crucial to respond to these inquiries promptly and thoroughly, as this can significantly impact the timeline of your review process.

Effective strategies for addressing comments include:

• Timely Responses: Ensure that all responses are provided within the deadlines set by the Notified Body. Timely feedback demonstrates professionalism and commitment to the process.
• Detailed Clarifications: Provide detailed explanations and additional data as necessary to clarify concerns raised. Make sure your responses directly address each point raised by the Notified Body.
• Utilize EU MDR Consulting Services: If necessary, consider leveraging EU MDR consulting services that can offer specialized insights and expertise in addressing technical or regulatory queries effectively.

Maintaining thorough documentation of all communications throughout this process is essential. This serves as a record of engagement and can be valuable if issues arise later in the evaluation process.

Step 6: Receiving and Implementing the Notified Body Opinion

Upon satisfactory completion of the review process, the Notified Body will issue their Opinion based on the submitted information. This Opinion is a critical milestone, as it serves as validation that your combination product meets EU MDR requirements.

In preparation for the receipt of the Opinion, ensure that the following steps are in place:

• Review the Opinion Document: Thoroughly analyze the issued Opinion for any conditional requirements or specific notes that must be addressed before market entry.
• Plan for Implementation: Establish a plan to implement any recommendations or conditions outlined in the Opinion, including potential changes to product labeling or additional studies if necessary.
• Engage with Regulatory Authorities: Prepare to engage with applicable regulatory authorities in your target markets, providing evidence of the NBOp as part of your pre-market submission.

Upon successful implementation of the Notified Body Opinion, US sponsors can proceed to launch their product in the European market, adhering to the strict regulations that govern the sale and distribution of medical devices under EU MDR.

Step 7: Post-Market Surveillance and Compliance

Post-approval compliance and surveillance are vital components in maintaining market authorization for your combination product. This step involves the diligent monitoring of device performance in the market to ensure ongoing safety and efficacy.

In this regard, you should:

• Establish and Maintain a Post-Market Surveillance System: Implement a robust post-market surveillance system designed to gather data on device performance, adverse events, and user feedback.
• Periodic Reporting Requirements: Develop processes to comply with periodic reporting requirements to the Notified Body and regulatory authorities, ensuring that you meet all stipulated timelines.
• Risk Management Updates: Regularly update your risk management file based on post-market feedback and any identified changes in the safety profile of the device.

By establishing an ongoing commitment to post-market surveillance and compliance, US sponsors can navigate the complexities of EU MDR successfully and support the long-term success and safety of their medical devices in the European market.

MDR Annex II Technical Documentation for Combination Products: Practical Template in 2023

The landscape of medical regulations continues to evolve, necessitating a thorough understanding of the requirements specified in the European Union Medical Device Regulation (EU MDR), particularly for combination products. This article provides a comprehensive, step-by-step tutorial on preparing the technical documentation as outlined in Annex II of the EU MDR. Aimed at US regulatory affairs professionals, this guide elucidates crucial documentation expectations and practical actions needed for successful compliance and submission.

Step 1: Understanding Combination Products and Regulatory Framework

Combination products, which integrate a drug with a device, present unique regulatory challenges. Before navigating the specifics of technical documentation under the EU MDR, a clear understanding of what constitutes a combination product is essential. The FDA defines combination products as products that combine drugs, devices, or biologics into a single entity. Each element must conform to the specific regulations of its category.

Under Article 117 of the EU MDR, combination products that include a medicinal product must comply with both the medical device and medicinal product regulations. It’s imperative to identify if your product is a combination product and ascertain the appropriate regulatory pathway. This clarification informs the responsibilities concerning conformity assessment, which is crucial in the preparation of technical documentation.

• Identify the product classification: Drug, device, or combination product.
• Determine applicable regulations: EU MDR, FDA guidelines, etc.
• Recognize the role of Notified Bodies which assess compliance before market entry.
• Understand the compulsory elements of Annex II documentation.

Step 2: Preparing Technical Documentation as per MDR Annex II

Annex II of the EU MDR outlines the requirements for technical documentation, requiring a thorough presentation of the safety and performance of the combination product. The technical documentation includes two primary sections: the general description of the product and the essential requirements, which specify safety and performance criteria.

Your technical documentation should incorporate the following key elements:

• Product Description: Include a detailed description of the product, including intended use, design, and components.
• Manufacturing Information: Address the manufacturing processes, including quality management systems in place (GSPR compliance).
• Safety and Performance Data: Summarize clinical data and literature that supports product safety and efficacy.
• Risk Management: Provide a comprehensive risk analysis conforming to ISO 14971, demonstrating identification and control of potential risks.

Documenting this information entails careful planning and assembly of relevant data from multiple sources. For example, to address safety concerns, clinical evaluation reports must be compiled, demonstrating that comprehensive studies have been carried out in compliance with GCP guidelines.

Step 3: Ensuring Compliance with General Safety and Performance Requirements (GSPR)

The General Safety and Performance Requirements (GSPR) outlined in Annex I of the EU MDR mandate that combination products must meet certain criteria to ensure safety and performance. This is where your robust preparation from the earlier steps pays dividends; meeting GSPR is a combination of both documented evidence and demonstrable effectiveness.

The GSPR consists of 23 requirements, including:

• Clinical Evaluation: Documentation should include evidence for clinical evaluations and post-market surveillance as part of the lifecycle management.
• Usability and Human Factors: Ensure that the product is designed with the end-user in mind, reducing potential misunderstanding and errors in use.
• Biocompatibility: As part of a device’s safety profile, demonstrate that materials that contact the body are safe.
• Performance Requirements: Specify the intended performance and confirm that it is verified through testing and reported outcomes.

Each requirement must be engaged thoroughly. The documentation needs to reflect adherence to each GSPR criterion, supported by laboratory tests, studies, and expert opinions. This phase will often involve collaboration across multiple disciplines, including clinical, engineering, and regulatory affairs teams.

Step 4: Integrating EUDAMED into Technical Documentation

As part of the EU MDR’s implementation, the European Database on Medical Devices (EUDAMED) plays a pivotal role in maintaining transparency and facilitating regulatory processes. Ensuring proper integration of EUDAMED information into your technical documentation is critical for compliance and market access.

When preparing documentation:

• Registration: All combination products must be registered in the EUDAMED database. Ensure that your product information, including the Unique Device Identifier (UDI), is accurately recorded.
• Keep Records Updated: Maintain dynamic documentation that reflects any amendments made during the approval process.
• Consent for Data Sharing: Be prepared to share certain data with the regulatory authorities, ensuring patient privacy is respected in compliance with GDPR guidelines.

By providing complete and accurate information in EUDAMED, you reduce the risk of compliance issues down the line. It is not just an administrative task; it directly contributes to the product’s integrity and safety perception.

Step 5: Collaborating with Notified Bodies for Technical Documentation Review

Collaboration with a Notified Body is an essential step in the submission process for combination products under the EU MDR. A Notified Body will conduct an evaluation of your technical documentation against established norms, confirming compliance with the given regulations, including Article 117 requirements.

To ensure a productive relationship with the Notified Body:

• Pre-Submission Meetings: Engage in preliminary consultations with the Notified Body to clarify any uncertainties regarding your documentation and submission process.
• Document Preparation: Ensure all documents are succinct, cohesive, and address the feedback offered by the Notified Body in prior interactions.
• Understand Fees and Timelines: Be familiar with the financial implications and timeframe anticipated for a complete review.

Document reviews aren’t one-time events; maintaining ongoing communication with your Notified Body can ease hurdles throughout the approval processes. It can also foster a deeper understanding of regulatory expectations and expectations from their perspective.

Step 6: Submission of Technical Documentation and Regulatory Filing

With your technical documentation polished and approval secured from the Notified Body, the next phase involves the formal submission process. This crucial step finalizes your entry into the marketplace in compliance with EU regulations.

The submission process includes:

• Compilation of Submission Dossier: Consolidate all technical documentation, including the required modules as outlined in Annex II. Make sure each module is meticulously organized.
• Cover Letter and Application Form: Include a clear cover letter detailing the submission and providing context. Complete the application forms thoroughly.
• Electronic Submission: If mandated, submit the entire package electronically via the designated channels. Ensure adherence to requirements regarding format and entry.

Once the application is submitted, regulators will initiate their review, assessing compliance against the requirements specified in the MDR. This stage might entail answering queries from the authorities and clarifying parts of your submission documentation. Prepare to act promptly to any requests for further information or documentation.

Step 7: Post-Approval Commitments and Market Surveillance

The final phase in the regulatory pathway does not conclude with the approval of your combination product. Maintaining compliance and commitment to post-approval activities is imperative to uphold standards and ensure continued market suitability.

Your obligations will include:

• Post-Market Surveillance: Establish and execute a post-market surveillance plan, including ongoing risk assessments to identify any issues that may arise post-launch.
• Vigilance Reporting: Adhere to vigilance requirements, reporting any adverse events or safety concerns in the designated timeframe.
• Periodic Safety Update Reports (PSUR): Depending on your product classification, compile and submit PSURs as a part of ongoing regulatory compliance and risk management.
• Maintain Quality Management Systems: Ensure continual improvement in quality management practices, consistently adapting them to regulatory standards and market needs.

Implementing an effective post-marketing strategy helps mitigate potential risks and signifies to regulatory bodies a commitment to product safety and efficacy. A rigorous adherence to these commitments serves as a testimony to your diligence and reliability as a manufacturer, ultimately fostering trust in your product.

GSPR Mapping for Drug–Device Systems: Evidence Matrix Approach in 2023

The regulation of drug-device combination products presents significant complexities, particularly under the EU MDR frameworks. This comprehensive guide aims to elucidate the approach of using an Evidence Matrix as a structured method for General Safety and Performance Requirements (GSPR) mapping concerning drug-device systems. In this tutorial, we will navigate through various steps that regulatory professionals must take to ensure compliance with the relevant directives, primarily focusing on the expectations under Article 117 and their implications for notified bodies.

Step 1: Understanding the Regulatory Framework for Drug-Device Systems

Before embarking on GSPR mapping, it is essential to comprehend the regulatory landscape surrounding drug-device combination products. The European Union’s Medical Device Regulation (EU MDR) lays out the necessary compliance pathways that pertain to these products, particularly under Article 117, which entails specific requirements for certain drug-device combinations. Understanding the interplay between the medical devices and medicinal products is foundational since each component’s regulatory requirements must be harmonized. This includes adherence to the European Medicines Agency (EMA) requirements, as well as considerations that fall under the purview of the European Commission.

Drug-device combinations may include products such as pre-filled syringes, inhalers, or drug-coated stents. Each component in these systems has distinctive regulatory avenues that must be navigated to ensure compliance. Key documents, including ISO standards (e.g., ISO 13485 for Quality Management Systems), and the GSPR detailed in Annex I of the EU MDR, serve as key references for regulatory professionals. Understanding GSPR is vital since it outlines the essential performance and safety requirements of devices, which must be demonstrated for all medical devices marketed in the EU.

Step 2: Initial Document Preparation for GSPR Mapping

Preparation is critical when beginning your GSPR mapping. Start with the development of a comprehensive documentation plan, which should include all necessary records concerning the drug-device combination. This will typically cover product design history, risk assessment reports, and existing test results. Each of these documents will play a pivotal role in the subsequent steps of the GSPR mapping process.

• Product Design History: Document all aspects of device and drug design, including intended use and claims.
• Device Specifications: Prepare specifications for both components within the combination product — the drug and device.
• Risk Assessment Reports: Using harmonized risk management standards, conduct a thorough risk assessment, linking hazards associated with the device to potential clinical outcomes.
• Clinical Investigation Data: For combination products involving novel therapeutics or innovative devices, compile relevant clinical data that supports safety and efficacy claims.

This foundational step lays the groundwork for effective GSPR mapping and enables a systematic review of product components through their respective regulatory lenses.

Step 3: Conducting GSPR Mapping with an Evidence Matrix

The core of the GSPR mapping process is to utilize an Evidence Matrix. This tool helps frame the information necessary to demonstrate compliance with GSPRs effectively. An Evidence Matrix typically contains columns for GSPR clauses from the EU MDR, applicable testing or documentation required, and existing data that corresponds to each requirement. Begin by transcribing each applicable GSPR clause into the matrix.

Next, for each GSPR clause:

• Identify the evidence required to demonstrate conformity.
• List existing data or tests that provide this evidence.
• Document any testing gaps or additional information needed to meet GSPR.

Ensure that Traceability is maintained, linking the claims made in your regulatory submissions back to the evidence documented within the matrix. This matrix will serve as a pivotal tool during both the submission and the review phases.

Step 4: Interaction with Notified Bodies

Communicating with Notified Bodies is an essential aspect of compliance in the drug-device regulatory landscape. As part of your GSPR mapping, it’s important to engage with appropriate notified bodies early in the process, particularly with those experienced in both drug and device evaluations. This will provide insights into the specific expectations surrounding GSPR compliance.

Prepare for the Notified Body interaction by:

• Submitting your Evidence Matrix for preliminary review.
• Addressing questions and issues that arise from this initial review to ensure clarity and compliance with GSPRs.
• Gathering requisite documentation to substantiate all claims made in your matrix.

This proactive strategy will enable a smoother review process, reduce the likelihood of contentious issues arising later, and facilitate robust understanding from both parties regarding regulatory expectations.

Step 5: Submission Preparation for Regulatory Review

Once the Evidence Matrix is completed and feedback has been integrated following discussions with the Notified Body, you will move into the preparation of the regulatory submission. The submission should adhere to the strict guidance outlined in the EU MDR, ensuring that all required documentation is complete and adequately detailed. The submission must include, at a minimum:

• Technical Documentation: Provide evidence that demonstrates compliance with the applicable GSPRs outlined in Annex II of the EU MDR.
• Clinical Evaluation Reports: Establish that the device performs safely and effectively when used as intended.
• Quality Management System Documentation: Provide an overview of quality management processes in place that govern manufacturing and quality assurance.

Ensure that your submission format is consistent with expectations set forth by both the Notified Bodies and the broader regulatory framework. Adhere strictly to submission deadlines and formats, including any electronic submissions required by regulatory bodies such as EUDAMED for registration.

Step 6: Engaging in the Review Process

Following submission, the review process ensues. During this phase, regulatory professionals should remain engaged and responsive. Expect to answer queries from the Notified Body and provide any additional information they require to facilitate a thorough evaluation. Key actions include:

• Timely Responses: Address any inquiries promptly, which assists in expediting the review period.
• Continuous Monitoring: Monitor the status of the review through agreed-upon channels, ensuring not to miss any updates that may necessitate further action on your part.
• Collaboration: Maintain open lines of communication with the Notified Body throughout the process.

Being proactive during the review process can significantly enhance the likelihood of receiving favorable opinions from the Notified Body regarding the safety and performance of your drug-device system.

Step 7: Post-Approval Commitments and Pharmacovigilance Requirements

The final step in the GSPR mapping process involves post-approval commitments and ensuring that ongoing compliance with regulatory requirements is maintained. This includes establishing robust post-market surveillance systems to monitor the performance of the drug-device combination after it has received CE marking. Essential components of this step include:

• Updating the Evidence Matrix: Post-market data must be continuously added to your Evidence Matrix, demonstrating ongoing compliance with GSPRs.
• Engaging in Pharmacovigilance Activities: Set up processes for reporting adverse events and ensuring that any safety concerns are swiftly addressed.
• Regular Reporting: Submit relevant reports to regulatory authorities periodically to confirm the continued safety and efficacy of the product.

Post-approval activities should be viewed as part of the lifecycle management of your product, requiring rigorous oversight and commitment to quality and safety standards.

UDI Strategy for Combination Products: US-to-EU Data Alignment in 2023

In an era of increasing global regulatory harmonization, understanding the Unique Device Identification (UDI) strategy for combination products becomes essential. This guide serves as a comprehensive step-by-step tutorial for regulatory affairs professionals, particularly those operating at the intersection of drug and device regulations. We will cover the essential phases of developing an UDI strategy that aligns with both US and EU regulations, ensuring effective compliance and successful market authorization.

Step 1: Understanding the Regulatory Framework for Combination Products

Before delving into the specifics of an UDI strategy, it’s crucial to establish a solid understanding of the regulatory frameworks governing combination products in the US and EU. Combination products are defined as therapeutic and diagnostic products that integrate both drug and device components.

In the United States, combination products are regulated by the FDA through a hybrid framework that combines the pathways for pharmaceuticals and medical devices. This requires understanding specific guidance documents such as the FDA’s guidance on combination products, and regulations outlined in 21 CFR Part 3.

On the EU side, the regulation of combination products falls under the **EU Medical Device Regulation (MDR)**, especially under **Article 117**, which outlines the specific requirements for products that combine a medical device with a medicinal product. It emphasizes compliance with both the General Safety and Performance Requirements (GSPR) as outlined in Annex I of the MDR.

For effective UDI implementation, compliance with the relevant databases is paramount, especially **EUDAMED**, the European database for medical devices, and part of the EU’s regulatory framework post-market. This familiarity lays the foundation for accurately aligning your UDI strategy across both jurisdictions.

Step 2: Conducting a UDI Gap Analysis

The next step involves a meticulous gap analysis that assesses the existing UDI compliance against the requirements of both the FDA and EU regulations. This gap analysis should encompass several core elements:

• UDI Requirements Comparison: Examine the differing UDI requirements between the FDA and EU. In the US, UDIs must be submitted to the FDA’s Global Unique Device Identification Database (GUDID) and include specific elements, whereas in the EU, the UDI needs to be part of the EUDAMED submission.
• Packaging and Labeling Review: Evaluate the labeling and packaging elements that contain UDI information in both jurisdictions. Ensure that all necessary data points, such as device identification, production identification, and expiration dates, are covered.
• Documentation Audit: Assess existing documentation related to UDI, such as design history files (DHFs) and device master records (DMRs), to ensure they meet the criteria set forth by regulatory authorities. This step is crucial for establishing compliant processes moving forward.

Executing a gap analysis will help identify discrepancies and areas needing enhancement to align with compliance expectations. The outcome should be a detailed report that delineates required actions, timelines for resolution, and responsibilities.

Step 3: Developing a UDI Strategy

Formulating a robust UDI strategy is vital, involving a cohesive plan that incorporates findings from the gap analysis while mapping out the necessary steps for compliance.

1. Define UDI Components: Identify and classify each component of the combination product. This classification should reflect both its device and drug parts to ensure UDI applicability per regulatory requirements.

2. Establish UDI Issuance Protocols: Decide whether the UDI will be obtained through the FDA-accredited issuing agency or through the issuing bodies recognized in the EU. For both regions, ensure that all UDI data elements are accurately captured and formatted in accordance with the respective regulations.

3. Implement Training Programs: Develop training materials for stakeholders, emphasizing the importance of UDI compliance and its utility in post-market surveillance. Ensure all personnel involved understand the operations related to acquiring, maintaining, and using UDI information effectively.

4. Continuous Quality Improvement: Establish metrics for evaluating the effectiveness of the UDI strategy. Set periodic reviews to assess compliance adherence and efficiency of UDI applications and processes.

Step 4: Quality Management System Integration

Integrating UDI strategy into an existing Quality Management System (QMS) is essential to ensure ongoing compliance and effectiveness. The QMS must reflect UDI processes seamlessly.

1. Document Control: Update existing QMS documentation to include UDI policies and procedures, emphasizing their role in product lifecycle management and regulatory compliance.

2. Risk Management: Incorporate risk management processes that specifically address the implications of UDI non-compliance. This will help in identifying hazards and implementing appropriate controls as per ISO 14971 standards.

3. Data Management Practices: Create systematic data storage and retrieval processes that protect UDI-related information while adhering to data protection regulations, including GDPR for the EU market.

With this integration, organizations can maintain consistency in compliance and provide an effective response mechanism in case of post-market requirements or issues linked to product identification and traceability.

Step 5: Preparing for Regulatory Submissions

Completing the UDI strategy necessitates preparation for regulatory submissions. Submissions must encompass all relevant UDI information aligned with both FDA and EU requirements.

1. Compile Necessary Documentation: Gather and prepare documentation required for UDI submission based on the findings from the gap analysis. Ensure that the UDI data elements match the requirements outlined in the FDA’s **GUDID** and the EU’s **EUDAMED**. Key documentation includes:

• Labels and packaging containing the UDI
• Device master records
• Design history files

2. Engage with Notified Bodies: Communications with the designated Notified Body are crucial for compliance with EU regulations, especially in areas concerning UDI. Submit necessary pre-market documents to them for review, and ensure your UDI strategy aligns with their expectations.

3. Establish Submission Timelines: Develop a timeline that captures the submission date for UDI and ensures it aligns with review timelines for product approval in both regions. Be mindful of regulatory deadlines to avoid delays.

These preparations are critical for successful regulatory approval and effective market access for combination products across jurisdictions.

Step 6: Post-Approval Compliance and Monitoring

Once regulatory approval is achieved, ongoing compliance monitoring of UDI is essential to sustain regulatory adherence. This phase should involve several practical steps.

1. Ensure Continuous Data Integrity: Implement robust data verification processes to maintain the accuracy of UDI information in GUDID and EUDAMED. Regular audits of UDI entries should be performed to identify discrepancies.

2. Monitor Changes to Regulatory Requirements: Stay abreast of regulatory changes that impact UDI requirements in both the FDA and EU frameworks. Participation in relevant workshops and updates from regulatory agencies can assist in remaining informed on compliance expectations.

3. Post-Market Surveillance and Reporting: Develop systems for post-market surveillance of combination products that include UDI-based data collection and analysis for adverse events, complaints, and tracking. Reporting these findings to the FDA and Notified Bodies as required is essential for compliance.

By implementing these compliance monitoring activities, companies can mitigate risks associated with non-compliance and proactively address emerging issues.

Conclusion and Final Steps

In conclusion, establishing and executing a UDI strategy for combination products with an eye toward alignment between the US and EU regulatory environments is a complex but achievable goal. By following structured steps from understanding regulations to meticulous post-approval monitoring, organizations can ensure robust compliance while facilitating strategic market access.

Compliance is an ongoing process that requires organizational commitment, thorough documentation, and active engagement with regulatory bodies. By integrating these practices into daily operations, companies can effectively manage the complexities of UDI implementation and uphold their commitment to patient safety and product efficacy.

PMS/PMCF Planning Under MDR for Drug–Device Products: Commercial Readiness in 2023

In the evolving landscape of medical device regulations, particularly under the European Union Medical Device Regulation (EU MDR), the complexities surrounding Post-Market Surveillance (PMS) and Post-Market Clinical Follow-up (PMCF) intensify for drug-device combination products. Ensuring compliance with these regulations is crucial for commercial success, particularly when navigating regulatory expectations from both the FDA and European authorities. This comprehensive guide provides a step-by-step approach to PMS and PMCF planning under MDR, aimed at enhancing your organization’s commercial readiness.

Step 1: Understand the Regulatory Framework for Drug-Device Products

The initial phase of PMS/PMCF planning involves a thorough understanding of the regulatory frameworks applicable to drug-device combination products. Drug-device products, classified as combination products under the FDA regime, must adhere to both pharmaceutical and medical device regulations. In the European context, such products are influenced by the EU MDR, notably Article 117, which mandates that products incorporating medicinal components meet specific criteria for safety and performance.

The first step in this process involves identifying the correct classification for the product. According to the EU MDR, drug-device combinations are categorized into two main groups: those where the principal intended action is that of the device (with the drug playing a complementary role), and vice versa. Understanding this classification is vital as it determines the regulatory expectations and scrutiny during the PMS/PMCF planning.

Additionally, graps of the General Safety and Performance Requirements (GSPR) is essential, as compliance with these requirements sets the foundation for the development of your PMS and PMCF plans. The GSPR is outlined in Annex I of the EU MDR and specifies a comprehensive set of safety and performance standards that a combination product must fulfill. There is also the necessity to consider relevant harmonized standards and guidelines set forth by Notified Bodies to ensure compliance.

Step 2: Develop a Comprehensive PMS Plan

Once the regulatory framework has been understood, the next step is to create a robust Post-Market Surveillance (PMS) plan. The PMS plan serves as a strategic document detailing how a company will monitor the safety and effectiveness of its combination product after it has been marketed. Here are the critical elements to include in your PMS plan:

• Objective Definition: Specify the objectives of your PMS activities, including identifying potential risks and verifying the safety and effectiveness of your product in real-world settings.
• Data Collection Methods: Establish methodologies for collecting post-market data. These methods can include passive surveillance (e.g., adverse event reporting) and active surveillance (e.g., registry studies).
• Data Analysis Plan: Define how the collected data will be analyzed, including identifying key performance indicators and safety thresholds.
• Communication Strategy: Outline the process for communicating PMS findings to healthcare professionals, regulatory authorities, and stakeholders, ensuring alignment with regulatory reporting obligations.
• Timeline and Responsibilities: Designate timelines for data collection and analysis while assigning responsibilities to specific team members or departments to ensure accountability.

The PMS plan must be tailored to the nuances of your drug-device product, adhering to EU MDR requirements while also considering FDA recommendations for combination products. It is advisable to establish a PMS working group comprising regulatory, clinical, and quality assurance experts to facilitate effective planning and execution.

Step 3: Prepare for PMCF Activities

Having developed a PMS plan, the next critical phase involves planning the Post-Market Clinical Follow-up (PMCF) activities. PMCF is a crucial element to ensure ongoing clinical safety and efficacy monitoring and often entails further clinical investigations or studies. The following steps will guide you through this process:

• Identify PMCF Objectives: Outline the clinical aspects that need further investigation. This could include evaluating long-term safety, addressing specific adverse event trends observed through PMS data, or gathering clinical data that supports the continued safety and performance of the product.
• Select Appropriate Study Design: Depending on your objectives, choose a suitable study design. This could range from observational studies to controlled trials. Ensure alignment with scientific integrity while balancing regulatory expectations.
• Engage with Notified Bodies: Prior to launching PMCF activities, consult with your Notified Body to validate your PMCF plan. This engagement can ensure alignment with regulatory expectations and streamline approval processes.
• Document and Submit PMCF Plans: Once your PMCF plan is finalized, comprehensively document all methodologies, objectives, and expected outcomes. This documentation becomes part of the technical dossier required for Notified Body review under the EU MDR guidelines.
• Data Management: Develop a robust data management plan to handle clinical data. Ensure compliance with personal data protection regulations (e.g., GDPR) throughout the PMCF activities.

PMCF must be a proactive endeavor, and continuous evaluation based on feedback from both PMS data and active clinical monitoring is vital. Regular updates to your PMCF program are essential as new data emerges or the market landscape changes.

Step 4: Assemble the Technical Documentation Dossier

With the PMS and PMCF plans in place, assembling the technical documentation dossier is the next critical step in demonstrating compliance with regulatory requirements. The technical file must include extensive information regarding the safety and efficacy of the product. Below are the main components you must include:

• Device Description: Provide an exhaustive description of the drug-device combination product, detailing its intended use, working principles, and the specific characteristics that qualify it as a combination product.
• Risk Management: Include a risk management report that evaluates potential risks associated with the device and outlines risk control measures implemented to mitigate those risks. This should align with the ISO 14971 standard.
• PMS and PMCF Plans: Incorporate your finalized PMS and PMCF plans into the dossier, which will provide evidence of the company’s commitment to ongoing monitoring of product safety and effectiveness.
• Clinical Evaluation Report (CER): Prepare a comprehensive Clinical Evaluation Report that summarizes clinical data gathered during studies and through PMS/PMCF activities, demonstrating compliance with regulatory requirements detailed in Article 61 of the MDR.
• Lifecycle Management: Document strategies for product lifecycle management, highlighting monitoring and updates based on real-world data and clinical feedback.

The complete technical documentation dossier should not only meet regulatory compliance requirements but also serve as an effective communication tool for engaging with regulatory authorities, Notified Bodies, and stakeholders in discussions regarding your product.

Step 5: Submit the Dossier to Notified Bodies

After the technical documentation is compiled, the dossier is ready for submission to a Notified Body. The submission process is critical and involves a series of steps:

• Pre-Submission Consultation: Engage in a pre-submission consultation with the Notified Body if feasible. This can provide valuable insights and guidance before formally submitting your application.
• Documentation Review: Ensure all documents are thoroughly reviewed for completeness and alignment with EU MDR requirements. Attention to detail is paramount as any inconsistencies can lead to delays or rejections.
• Formal Submission: Submit your technical dossier along with the necessary fees to the chosen Notified Body. Ensure to keep track of submission receipts and correspondence.
• Follow-Up Communications: Maintain open lines of communication with the Notified Body post-submission. Be prepared for queries and provide additional information expeditiously as needed.
• Prepare for Audits: Understand that the Notified Body may conduct audits as part of the review process. Ensure that your internal processes are in line with regulatory standards, and documentation is readily available for review.

Approval from the Notified Body is crucial for the commercialization of your drug-device product in the EU. Maintain clear communication throughout the process to facilitate a smoother approval journey.

Step 6: Monitor Post-Market Performance and Compliance

Upon receiving approval and launching the drug-device combination product, continuous monitoring ensues. Ongoing PMS and PMCF activities are vital to ensure that your product remains compliant and safe for end-users. Here’s how to effectively monitor post-market performance:

• Data Collection and Identification of Signals: Utilize the methods established in your PMS plan to collect data continuously. Identify adverse events and any signals that warrant further investigation promptly.
• Update PMS and PMCF Plans: Regularly evaluate the effectiveness of your PMS and PMCF processes. Update these plans based on the latest data, ensuring they remain relevant to the evolving safety and performance landscape.
• Regulatory Reporting: Adhere to regulatory obligations to report adverse events or changes in risk profiles to the relevant authorities, including the EMA and Notified Bodies. The frequency and specifics of reporting will depend on the product classification and the nature of the reported events.
• Stakeholder Communication: Communicate findings from PMS and PMCF activities to stakeholders, including healthcare professionals, regulatory bodies, and patients. Effective communication will enhance trust and ensure that all parties remain informed about product performance.
• Collaborate with QA Teams: Work closely with Quality Assurance teams to ensure that all methodologies align with good manufacturing practices and required quality standards.

The post-market phase is a dynamic period, and companies must be proactive in addressing any regulatory or safety concerns promptly. Adapting to real-world data and feedback enhances product credibility and market relevance.

Step 7: Prepare for Renewals and Continuous Compliance

The regulatory landscape is ever-evolving, and it is essential to prepare for renewals and maintain continuous compliance. Understanding when and how to renew approvals is crucial. Here are the key considerations:

• Regulatory Renewal Timelines: Familiarize yourself with the renewal timelines established by the Notified Body. Ensure timely submissions to avoid gaps in compliance.
• Continuous Documentation Updates: Regularly update your technical documentation to reflect changes in your PMS and PMCF activities, as well as any amendments to the GSPR or other regulatory requirements.
• Engagement with Regulatory Authorities: Maintain an ongoing relationship with regulatory bodies. Engage in dialogues regarding regulatory changes and how they impact your product’s compliance and performance.
• Training and Education: Keep your team apprised of the latest regulatory changes and best practices. Continuous training and education are essential for adherence to evolving standards.

By anticipating the need for renewals and maintaining a culture of compliance within the organization, drug-device products can navigate the complexities of regulatory requirements while ensuring ongoing safety and efficacy for users.

EUDAMED Registration Readiness for Combination Products in 2023: Data Elements and Governance

In the context of the European Union’s Medical Device Regulation (EU MDR), the European Database on Medical Devices (EUDAMED) plays a critical role in enhancing the transparency and coordination of information regarding medical devices and their safety. Combination products, which comprise both drugs and devices as defined under Article 117 of the EU MDR, must adhere to specific regulatory processes, including EUDAMED registration. This article provides a structured, step-by-step tutorial for regulatory professionals who wish to ensure that their combination products are ready for EUDAMED registration, with a focus on practical actions and documentation.

Step 1: Understanding EUDAMED and Its Role in Combination Product Regulation

EUDAMED is an essential element of the EU MDR, intended to promote the safety and effectiveness of medical devices, including combination products. As a comprehensive database, it consolidates information from various stakeholders, including manufacturers, Notified Bodies, and competent authorities. Understanding this framework is pivotal for ensuring compliance with EU regulations.

Combination products, which are defined as products that combine a drug and a device, bring unique regulatory challenges, especially concerning their classification, labeling, and documentation requirements. Under Article 117 of the EU MDR, specific requirements must be met, and as such, manufacturers need to be prepared to meet the comprehensive data requirements associated with both drug and device components.

Prior to undertaking registration in EUDAMED, it is paramount to assess whether your product aligns with the definitions outlined in the EU MDR and to identify the components that will necessitate distinct regulatory pathways. A deep understanding of the General Safety and Performance Requirements (GSPR) in Annex II is essential here, as they set the foundational standards for the safety and effectiveness of combined products.

Step 2: Preparation of Required Documentation for EUDAMED Registration

Preparing the necessary documentation is a crucial step toward EUDAMED registration. The primary documents required include the following:

• Design Dossier: This should detail the design, development, and performance data of the combination product. Emphasize compliance with the GSPR.
• Clinical Evaluation Report (CER): Ensure that your CER considers both the device and medicinal aspects of the combination product. Reference data should encompass clinical studies and post-market surveillance results.
• Risk Management File: Include a comprehensive risk assessment that complies with ISO 14971, demonstrating how risks associated with both components are identified and mitigated.
• Labeling and Instructions for Use (IFU): Develop labeling that clearly defines the use and purpose of both the drug and device components, complying with Article 10 of EU MDR.

Each document must satisfy the formal documentation expectations set forth by the EU regulations. Document control is critical; therefore, it is advisable to implement a quality management system that complies with relevant standards, such as ISO 13485. Documentation should be reviewed regularly for relevance and accuracy to maintain regulatory readiness.

Step 3: Engagement with a Notified Body

Manufacturers of combination products must engage with a Notified Body to validate compliance with the applicable regulatory requirements. Choosing the right Notified Body is foundational; it should possess expertise in both device and pharmaceutical regulations. The selection process includes:

• Assessment of Notified Body’s Scope: Check whether the Notified Body has the necessary scope of designation concerning combination products.
• Submission of Technical Documentation: Prepare for the submission process, ensuring all documentation is precise, coherent, and aligned with EU requirements.
• Communication of Regulatory Strategy: Maintain open lines of communication with your Notified Body to clarify expectations and timelines.

The Notified Body will assess the conformity of the combination product against the applicable harmonized standards and regulatory requirements. Successful engagement with them entails preparation for audits and assessments and prompt responses to any queries related to the product.

Step 4: Entering Data into EUDAMED

Once diligent preparations and successful evaluations are in place, the next step is to enter relevant product data into EUDAMED. This phase necessitates an in-depth understanding of the platform and its requirements:

As part of the registration process, companies must:

• Create a Unique Device Identifier (UDI): Ensure to generate a UDI for the combination product, which is critical for traceability and regulatory tracking.
• Develop and Submit Device and Clinical Data: In EUDAMED, you must provide detailed information regarding the product’s characteristics, clinical data, intended use, and the results of clinical evaluations. Make certain that data provided regarding the device and medicinal ingredient clearly complements each other.
• Compliance with Governance Requirements: Ensure adherence to the governance structure related to data input, incorporating all necessary stakeholders in the documentation process.

It is crucial to select appropriate technical teams trained in EUDAMED functionality to support data entry and accuracy. Any discrepancies or inaccuracies may lead to significant regulatory repercussions and hinder market access.

Step 5: Post-Approval Monitoring and Compliance Commitments

Following successful registration and market entry via EUDAMED, manufacturers must continue to uphold regulatory commitments through continuous monitoring and compliance management. Key post-approval actions include:

• Vigilance Reporting: It is mandatory to report any serious incidents related to the combination product to competent authorities as part of vigilance obligations. Establish a robust adverse event reporting system.
• Periodic Safety Update Reports (PSURs): Regularly prepare and submit PSURs that demonstrate ongoing compliance and product safety over time.
• Updating EUDAMED Information: Ensure that any changes to the technical documentation, intended use, or product characteristics are promptly updated in EUDAMED to reflect real-time data.

Engaging in proactive risk management and quality assurance processes throughout the product lifecycle is essential to maintain compliance with regulatory expectations. Continuous training and updates for the regulatory affairs team can foster a culture of compliance and enhance operational readiness for future submissions.

In conclusion, achieving EUDAMED registration readiness for combination products requires a structured, actionable approach focused on regulatory compliance, thorough documentation, and an understanding of governance principles. By following this step-by-step guide, stakeholders can better prepare for successfully navigating the complex regulatory landscape.

EU MDR vs US Combination Product Rules: Global Strategy for US Manufacturers in 2023

Global manufacturers of combination products face distinct regulatory pathways in the European Union (EU) and the United States (US). Understanding these differences is critical for successful compliance and market access. This article provides a step-by-step tutorial aimed at US manufacturers, detailing the regulatory framework associated with the EU Medical Device Regulation (MDR), particularly in relation to Article 117, GSPR, Notified Bodies, and EUDAMED. We will also explore how these UK and EU regulations align, diverge, and impact US combination product rules.

Step 1: Understanding Combination Products Regulations in the US and EU

In the US, combination products are regulated under a hybrid framework that involves separate divisions of the FDA overseeing drug, device, or biological components. These products can be a single entity, co-packaged, or cross-labeled, and regulations can vary significantly depending on the primary mode of action. Conversely, EU regulations treat combination products through the lens of applicable medical devices or medicinal products based on their primary use.

For US manufacturers entering the EU market, familiarity with the EU MDR is a mandatory prerequisite. The EU MDR, which was implemented on May 26, 2021, replaced the previous Medical Device Directive (MDD) and establishes stringent requirements on design, production, and post-market surveillance.

• US Regulations: Governed by the Federal Food, Drug, and Cosmetic Act (FDCA). The FDA delineates between drugs, biologics, and devices.
• EU Regulations: Governed by the EU MDR, which places clear emphasis on risk management and post-market responsibilities.

Understanding the classification of your product is the first step. Determining if your combination product is primarily a drug or device will dictate the regulatory pathway you must follow.

Step 2: Classification of Combination Products

Correct classification is vital as it influences the regulatory submission process and required documentation. In the EU, the classification process considers the intended use and mode of action, evaluating whether the product qualifies as a device, a drug, or both:

• Determine the primary intended purpose of the combination product.
• Consult the relevant guidance documents from the European Medicines Agency (EMA) for classification rules.
• Consider any supporting documentation that can substantiate claims regarding the device’s functionality.

In the US, the FDA classification system includes 3 classes (Class I, II, or III) based on risk assessment and intended use, which also applies to combination products. Manufacturers should utilize the FDA’s formal classification guidance documentation before beginning the regulatory submission process.

Establishing the correct classification upfront influences everything downstream, from clinical evaluation to market surveillance responsibilities.

Step 3: Preparing the Technical Document Dossier for EU MDR Compliance

The technical documentation dossier serves as an essential artifact in demonstrating conformity to the EU MDR. For combination products, the formation of this dossier requires adherence to Annex II of the EU MDR alongside relevant GSPR (General Safety and Performance Requirements). Key components include:

• Device Description: Provide a description of the product, intended use, and its components.
• Conformity Assessment: Identify the Notified Bodies that will conduct the review and ensure compliance with applicable EN standards and ISO regulations.
• Clinical Evaluation: Develop a thorough clinical evaluation plan that demonstrates safety and efficacy, which is particularly critical for combination products.
• Risk Management: Implement a risk management plan compliant with ISO 14971 to identify and mitigate potential risks to patients.
• Post-market Surveillance Plan: Outlining post-market evaluation mechanisms aligned with the requirements of Article 117 and respective GSPR provisions.

The comprehensive preparation of this dossier is crucial, as it will be the foundation for the Conformity Assessment procedure initiated with your Notified Body prior to market entry in the EU. Ensuring completeness and accuracy of the dossier can significantly reduce the likelihood of extensive queries and improve the chances of successful approval.

Step 4: Engaging with Notified Bodies

In the EU context, Notified Bodies play a critical role in validating compliance with the EU MDR. Manufacturers must initiate a partnership early if they intend to bring combination products to market:

• Select Appropriate Notified Body: Choose a Notified Body that has the necessary scope for the product classification. Verify accreditation status with the NANDO database.
• Plan for Communication: Establish a transparent dialogue early on to align expectations and clarify requirements.
• Documentation Requirements: Ensure that all reports, clinical data, and technical documentation are prepared to align with Notified Body requirements.
• Audits and Assessments: Prepare for both initial and periodic audits, keeping in mind that Notified Bodies will conduct on-site assessments of manufacturing sites under their supervision.

The collaboration with Notified Bodies is not just procedural. It is vital for advancing product lines and for maintaining momentum in the regulatory process.

Step 5: Regulatory Submission Process

The submission process differs significantly when comparing submissions to the FDA and EU requirements. In the US, manufacturers can submit through a 510(k), PMA, or NDA, depending on the classification of the combination product:

• 510(k) Submission: Often requires evidence of substantial equivalence with a legally marketed device.
• PMA Application: Mandated for Class III products, necessitating extensive clinical data.

For the EU submissions, manufacturers must ensure that they have completed all necessary documentation before applying for CE marking, which is validated through the selected Notified Body. Key submission milestones include:

• Compilation and submission of the Technical Documentation.
• Preparation and submission of the Clinical Evaluation Report.
• Application for CE marking, accompanied by the Declaration of Conformity.

Properly following through with each step in the submission process is imperative to expedite approvals and maintain regulatory compliance.

Step 6: Navigating EUDAMED Registration and Reporting

The European Database on Medical Devices (EUDAMED) improves transparency and maintains a comprehensive record of devices in the EU market. All manufacturers of combination products must safeguard compliance with EUDAMED regulations that include registration of devices, clinical investigations, and vigilance reporting.

• Registration: All manufacturers and products must be registered within EUDAMED prior to market entry, mapping the appropriate classes and categories.
• Vigilance Reporting: Establish structured procedures for vigilance and adverse event reporting aligned with EU’s MEDDEV guidance.
• Continuous Updates: Update EUDAMED actively to ensure the database reflects the latest information related to your combination products.

Failure to appropriately register or update information can result in fines and penalties, complicating ongoing market presence.

Step 7: Post-Market Surveillance and Commitments

Once market authorization is achieved, both the EU and US regulatory environments demand robust post-market surveillance programs to monitor product performance and safety:

• Ongoing Monitoring: Implement a system for continuous data collection to analyze the safety profile of your combination product.
• Risk Management Review: Regularly update the Risk Management Plan based on post-market performance data.
• Periodic Safety Update Reports (PSUR): Prepare and submit PSURs as required by the EU regulations.

Creating effective mechanisms for post-market surveillance will aid manufacturers in sustaining compliance and adapting quickly to any emerging issues.

Conclusion: Establishing a Global Regulatory Strategy

Current trends indicate that US manufacturers need to establish an integrative global strategy that not only incorporates compliance with US regulations but also comprehends and aligns with the rigorous demands of the EU MDR. By understanding classification pathways, preparing appropriate technical documentation, and engaging with Notified Bodies, manufacturers can position themselves favorably in this complex regulatory environment. Leveraging EU MDR consulting services can further streamline the process, ensuring compliance and enhancing product success across international markets.

FDA Regulatory Centers for Combination Products: CDER, CBER, CDRH

In the ever-evolving landscape of pharmaceuticals, understanding the regulatory pathways for combination products is critical for healthcare professionals involved in drug development. Combination products are therapeutic or diagnostic products that combine drugs, devices, and/or biological products. This comprehensive guide aims to provide a detailed, step-by-step approach to navigating the regulatory frameworks established by the FDA’s centers: the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Devices and Radiological Health (CDRH).

Step 1: Understanding Combination Products and Their Regulatory Centers

Before diving into regulatory submissions and compliance, it is essential to understand what combination products are and how they are regulated. A combination product may take multiple forms, including a drug-eluting device, a prefilled syringe, or a biological agent incorporated into a drug product. The nature of these products may dictate which of the FDA centers is responsible for their evaluation:

• CDER: Focuses primarily on drug products, including pharmaceuticals and certain biologics.
• CBER: Evaluates biological products such as vaccines, blood components, and cell therapies.
• CDRH: Responsible for medical devices and their safety and effectiveness.

Understanding the overlap and distinctions among these centers is fundamental to effective regulatory planning. Each center adheres to its specific regulatory framework, which may include different submission types such as New Drug Applications (NDA), Biologics License Applications (BLA), Premarket Approvals (PMA), and 510(k) submissions.

Step 2: Determining the Lead Center for Your Combination Product

Determining which FDA center will be the lead agency for your combination product is crucial for streamlining the review process. The FDA Office of Combination Products (OCP) plays a central role in this determination by evaluating the primary mode of action (PMOA) of the combination product.

The PMOA refers to the most significant therapeutic effect of the product. A thorough analysis involving the following criteria is necessary:

• Evaluation of the Primary Mode of Action: Identify whether the drug, device, or biological component has the most critical impact on the therapeutic effect.
• Guidance Documents: Review relevant FDA guidance documents to clarify the distinctions and requirements associated with the lead center.
• Consultation with FDA: If uncertainty persists, businesses may request a formal meeting with the OCP to discuss the proper classification and regulatory pathway.

Proper lead center designation is pivotal because it directly impacts the type of submission required and the regulatory expectations that will follow.

Step 3: Preparing the Regulatory Submission Dossier

Once you have identified the lead center, the next step is to commence the preparation of the regulatory submission dossier. Each submission type has a unique structure, but several common documents are generally required across the FDA evaluations. The preparation of your submission dossier requires careful organization and detailed documentation:

Essential Documents for Submission

• Product Description: Provide a comprehensive overview of the combination product, detailing each component’s role and the intended use.
• Quality Control Documentation: Include information about the manufacturing process, quality control measures, and compliance with Current Good Manufacturing Practices (CGMP).
• Non-Clinical Studies: Compile data from preclinical studies that establish the safety and efficacy of the combination product.
• Clinical Investigations: If clinical data is required, outline the study design, protocols, and statistical analyses used. Ensure compliance with Good Clinical Practice (GCP) guidelines.
• Labeling and Instructions for Use (IFU): Create patient-centric labeling and IFUs that comply with both drug and device regulations.

In addition, consider including:

• Risk Analysis: Conduct thorough risk assessments according to ISO 14971 for medical devices, ensuring all potential risks are mitigated.
• Regulatory History: If applicable, include the regulatory history of earlier versions or related products.
• Environmental Assessment: Depending on the product, you may need to submit an environmental assessment per FDA regulations.

Careful attention to the structure and completeness of the submission dossier minimizes the risk of Request for Additional Information (RAI) and expedites the review timeline.

Step 4: Selecting the Appropriate Regulatory Pathway

The regulatory pathway for a combination product hinges on its classification, which is determined by its construction and intended use. The typical pathways include:

• NDA/BLA: For combination products deemed primarily therapeutic drugs or biological products. NDA or BLA submissions usually include comprehensive data to justify drug regimens, efficacy, and safety data.
• PMA: For devices that require extensive clinical trial data to establish safety and effectiveness.
• 510(k): Typically utilized for devices that can be shown to be “substantially equivalent” to a legally marketed predicate device. This is less burdensome but still requires clear evidence of safety and effectiveness.

Selecting an appropriate pathway involves assessing the intended use and PMOA of the combination product while complying with investigational and post-marketing requirements. The FDA’s decision on whether a 510(k) or PMA is needed hinges on this classification.

Step 5: Engaging in FDA Review Process

After submission, the product undergoes the FDA review process, which may involve the following phases:

• Acceptance Review: The FDA reviews the submission for completeness. You may receive an acceptance letter or a request for additional information.
• Mid-Review Meetings: During the review, the FDA may reach out for clarification or additional data, particularly for combination products involving complex interactions.
• Final Review: A multidisciplinary review team evaluates safety and efficacy based on submitted data. Feedback may include review panels or advisory committees.

Understanding the review timeline and being prepared for any inquiries during this period is essential for maintaining a good rapport with the FDA and ensuring a smooth review process. Regular communication, clear documentation, and timely responsiveness to FDA inquiries can significantly impact review outcomes.

Step 6: Post-Approval Commitments and Compliance

Upon approval of a combination product, ongoing responsibilities must be adhered to for compliance:

• Post-Market Surveillance: There may be requirements for post-market studies to evaluate long-term safety and efficacy.
• Adverse Event Reporting: Any adverse events related to the combination product must be reported to the FDA. Familiarity with reporting practices is crucial.
• Labeling Updates: Monitoring for necessary updates to product labeling based on new safety data.

Adhering to post-approval commitments not only ensures continued compliance but also fosters sustained market success and maintains patient safety.

Step 7: Seeking Expert Consultation and Continuous Learning

Navigating the complexities of FDA combination product regulation can be challenging. Engaging in FDA combination product consulting can provide valuable insights and data-driven strategies. Consultants with expertise in federal regulations can assist your team throughout the process, from product development to post-marketing compliance.

Consider participating in workshops, conferences, and webinars to keep abreast of changes in regulatory expectations and clinical practices. Networking with industry peers and regulatory professionals can also foster best practices and innovative compliance strategies.

In conclusion, understanding the regulatory landscape for combination products is paramount for successful development and commercialization. By following this step-by-step guide and remaining compliant with FDA standards, businesses can navigate the regulatory process effectively, ensuring that their products reach the market and serve their intended purpose safely and effectively.

RFD (Request for Designation): When and How to File

In the landscape of regulatory affairs, understanding the intricacies of submitting a Request for Designation (RFD) to the FDA is crucial for firms working with combination products. This comprehensive guide delineates practical steps, regulatory requirements, and documentation expectations, paving the way for compliance and successful product development. This tutorial will benefit regulatory professionals involved in FDA combination product consulting, providing a structured approach to RFD submissions and the regulatory process surrounding them.

Step 1: Understand the Definition and Types of Combination Products

Before initiating a Request for Designation, it’s essential to clarify what constitutes a combination product under FDA regulations. A combination product involves a combination of two or more regulated components: a drug, a device, or a biological product. The FDA defines three primary types of combination products:

• Drug-Device Combinations: Products that include both a drug and a device component, such as prefilled syringes.
• Biologic-Device Combinations: Products that consist of a biological product combined with a device, for instance, drug-eluting stents.
• Drug-Biologics Combinations: These combine drugs and biologics into a single treatment modality.

The significance of correctly categorizing your product is paramount as it determines the regulatory pathway and the specific FDA office (CDER or CDRH) responsible for its approval. Understanding the specific elements of your product will also inform your pitch when preparing the RFD.

Regulatory insights can be gained from the official FDA resource on combination products, facilitating a clearer understanding of your product’s classification and the requisite regulatory oversight.

Step 2: Determine the Need for an RFD

The purpose of an RFD is to obtain FDA’s feedback on the classification of your combination product. Initiating this request is crucial when:

• The product’s classification is ambiguous or not clearly defined by existing regulations.
• The potential for different regulatory interpretations exists.
• You seek to ensure alignment with the appropriate regulatory pathway.

This step also entails reviewing your product’s components and intended use. An analysis of previous FDA decisions on similar products can lend additional perspective. Gathering insights from industry best practices may also present valuable context as you prepare your submission.

In assessing need, consider documented communications with the FDA, past classifications of similar products, and regulatory precedents that may impact your submission. Understanding the nuances of the FDA Office of Combination Products (OCP) can also guide your decision-making process.

Step 3: Prepare the RFD Submission

The next step is to prepare the RFD submission comprehensively. The FDA has outlined specific content requirements for RFD submissions focusing on clarity and completeness:

• Cover Letter: This should include your product name, and a brief description along with the determination request.
• Description of the Product: Provide extensive information about the components, intended use, and how they work together.
• Classification Information: Include a discussion of the regulatory classifications you believe are appropriate for your product based on its intended use.
• Supporting Data: Attach any data or information that supports your classification request, including clinical and scientific evidence.

Ensure that the information provided is well-organized and adheres to the expectations set forth by the FDA. Proper formatting and clear articulations will facilitate the review process. It’s wise to reference FDA guidance documents on combination products which can provide greater specificity on documentation expectations.

Utilizing available templates from the FDA can also streamline the organization and presentation of your information. Templates can be found on various regulatory platforms, aiding in ensuring compliance with FDA regulations.

Step 4: Submission Process to the FDA

Once you have prepared your RFD, the next phase is the submission process itself. Submissions should be sent electronically through the FDA’s Electronic Submissions Gateway (ESG) to ensure timely processing and acknowledgment of receipt. Follow these key steps during submission:

• Register with ESG: Ensure you have an active registration with the Electronic Submissions Gateway. This will facilitate the electronic submission process.
• Review Submission Guidelines: Ensure your RFD aligns with current FDA guidelines for electronic submissions, including formatting and file requirements.
• Submit Through ESG: Transmit your submission through the ESG, ensuring you retain confirmation of your submission for your records.
• Track Submission Status: After submission, regularly check the status through the FDA’s corresponding communication channels.

An essential aspect of the submission process is to remain responsive to any inquiries or requests from the FDA following your RFD submission. Maintaining open lines of communication can expedite resolution and clarity on classification decisions.

Review of the submission will typically take around 60 days, in which time the FDA will evaluate the provided information and classify the product accordingly. It is critical during this period to be prepared to address any queries the agency may have regarding the RFD.

Step 5: Understand FDA’s Response and Classification Determination

After the submission review period, the FDA will issue a response. Understanding the components of the response is vital for navigating the next steps:

• Classification Decision: The FDA will specify whether the product is classified as a drug, device, or biological product, or a combination thereof.
• Regulatory Pathway: The response will outline the appropriate regulatory requirements, including the type of pre-market submission needed (NDA, BLA, PMA, 510(k)).
• Additional Feedback: The FDA may provide recommendations or additional information needed to align your submission with established guidelines.

It’s integral to comprehend the implications of the classification decision, as this will dictate the pre-market regulatory pathway you must pursue. Each pathway, whether it be NDA for drugs, BLA for biologics, or 510(k) for devices, possesses distinct requirements. Carefully review the coverage for each applicable submission to ensure your compliance and readiness for subsequent stages.

Documentation of the FDA’s classification determination is crucial as it acts as a foundational element for future regulatory submissions, aligning product development with compliance regulations. Empower yourself by reviewing documents from the FDA regarding regulatory pathways for combination products.

Step 6: Preparing for Subsequent Regulatory Submissions

With the RFD response received and classification confirmed, you are now ready to move toward the next stage of product development, which often necessitates preparing for a formal pre-market submission. Depending on the classification, this will involve either:

• New Drug Application (NDA): For drugs that are new for exemption under the Food, Drug, and Cosmetic Act.
• Biologics License Application (BLA): For biological products requiring a new biological license.
• Premarket Approval (PMA): For devices that need rigorous assessment through clinical evaluation.
• 510(k) Application: For devices proving substantial equivalence to a legally marketed device.

In preparing these submissions, adhere to comprehensive regulatory guidelines provided by the FDA, while maintaining cross-discipline collaboration among your teams (regulatory affairs, clinical, quality assurance). This interdisciplinary approach will help ensure a holistic understanding of regulatory expectations and facilitate an efficient workflow.

Taking proactive measures in the form of pre-submission meetings with the FDA can initiate a dialogue that enhances the quality of your submission and aligns your product’s clinical and operational strategies with regulatory requirements.

Step 7: Post-Approval Commitments and Monitoring

Once your submission is approved, ensure that you remain compliant with post-approval regulatory obligations. This may include:

• Adverse Event Reporting: Monitoring and reporting any adverse events that arise post-market.
• Post-Market Surveillance Studies: Conducting studies as mandated by the FDA to further understand the safety and effectiveness of your product in real-world conditions.
• Labeling Changes: Updating product labeling according to newly-identified risks or safety information gleaned from post-market surveillance.

Documentation and tracking of these activities are critical components of maintaining regulatory compliance. Establish thorough processes for communicating findings, outcomes, and any necessary actions to the FDA. Staying informed of changes to regulations and responding intelligently will enhance your organization’s credibility and foster trust in your product line.

Engaging with regulatory consultants experienced in FDA combination product consulting can add further value in navigating ongoing compliance and post-marketing obligations.

The landscape of combination products is complex and multifaceted. By following these structured steps, you can effectively navigate the intricacies of submitting an RFD, preparing necessary documentation, and complying with regulatory requirements. Understanding each phase’s expectations will facilitate successful product development and market acceptance.